109 related articles for article (PubMed ID: 16799190)
1. Nucleotide metabolism and cell-cell interactions.
Eltzschig HK; Weissmüller T; Mager A; Eckle T
Methods Mol Biol; 2006; 341():73-87. PubMed ID: 16799190
[TBL] [Abstract][Full Text] [Related]
2. CD73-dependent generation of extracellular adenosine by vascular endothelial cells modulates
Jaeckstein MY; Schulze I; Zajac MW; Heine M; Mann O; Pfeifer A; Heeren J
Front Immunol; 2023; 14():1308456. PubMed ID: 38264660
[TBL] [Abstract][Full Text] [Related]
3. Beyond the barrier: the immune-inspired pathways of tumor extravasation.
Di Russo S; Liberati FR; Riva A; Di Fonzo F; Macone A; Giardina G; Arese M; Rinaldo S; Cutruzzolà F; Paone A
Cell Commun Signal; 2024 Feb; 22(1):104. PubMed ID: 38331871
[TBL] [Abstract][Full Text] [Related]
4. Extracellular adenosine signaling in molecular medicine.
Eltzschig HK
J Mol Med (Berl); 2013 Feb; 91(2):141-6. PubMed ID: 23338058
[No Abstract] [Full Text] [Related]
5. Allopurinol Disrupts Purine Metabolism to Increase Damage in Experimental Colitis.
Worledge CS; Kostelecky RE; Zhou L; Bhagavatula G; Colgan SP; Lee JS
Cells; 2024 Feb; 13(5):. PubMed ID: 38474337
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-adenosine axis as therapeutic targets for acute respiratory distress syndrome.
Figarella K; Kim J; Ruan W; Mills T; Eltzschig HK; Yuan X
Front Immunol; 2024; 15():1328565. PubMed ID: 38312838
[TBL] [Abstract][Full Text] [Related]
7. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Yuan X; Ruan W; Bobrow B; Carmeliet P; Eltzschig HK
Nat Rev Drug Discov; 2024 Mar; 23(3):175-200. PubMed ID: 38123660
[TBL] [Abstract][Full Text] [Related]
8. Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine.
Liang Y; Ruan W; Jiang Y; Smalling R; Yuan X; Eltzschig HK
Nat Rev Cardiol; 2023 Nov; 20(11):723-737. PubMed ID: 37308571
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner.
Tang T; Huang X; Lu M; Zhang G; Han X; Liang T
Nat Commun; 2023 Jun; 14(1):3364. PubMed ID: 37291128
[TBL] [Abstract][Full Text] [Related]
10. Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling.
Ruan W; Li J; Choi S; Ma X; Liang Y; Nair R; Yuan X; Mills TW; Eltzschig HK
JCI Insight; 2023 Jun; 8(11):. PubMed ID: 37288658
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Intermittent Hypoxia-Hyperoxia Therapy in Different Pathologies with Possible Metabolic Implications.
Uzun AB; Iliescu MG; Stanciu LE; Ionescu EV; Ungur RA; Ciortea VM; Irsay L; Motoașcă I; Popescu MN; Popa FL; Pazara L; Tofolean DE
Metabolites; 2023 Jan; 13(2):. PubMed ID: 36837800
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude.
Guo Q; Li X; Li W; Wang R; Zhao A; Wang Z
Drug Des Devel Ther; 2023; 17():75-85. PubMed ID: 36686057
[TBL] [Abstract][Full Text] [Related]
13. IFN-stimulated metabolite transporter ENT3 facilitates viral genome release.
Hsieh YT; Tsai TL; Huang SY; Heng JW; Huang YC; Tsai PY; Tu CC; Chao TL; Tsai YM; Chang PC; Lee CK; Yu GY; Chang SY; Dzhagalov IL; Hsu CL
EMBO Rep; 2023 Mar; 24(3):e55286. PubMed ID: 36652307
[TBL] [Abstract][Full Text] [Related]
14. Ectonucleoside triphosphate diphosphohydrolase-1 (CD39) impacts TGF-β1 responses: insights into cardiac fibrosis and function following myocardial infarction.
Novitskaya T; Nishat S; Covarrubias R; Wheeler DG; Chepurko E; Bermeo-Blanco O; Xu Z; Baer B; He H; Moore SN; Dwyer KM; Cowan PJ; Su YR; Absi TS; Schoenecker J; Bellan LM; Koch WJ; Bansal S; Feoktistov I; Robson SC; Gao E; Gumina RJ
Am J Physiol Heart Circ Physiol; 2022 Dec; 323(6):H1244-H1261. PubMed ID: 36240436
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
Wing PAC; Prange-Barczynska M; Cross A; Crotta S; Orbegozo Rubio C; Cheng X; Harris JM; Zhuang X; Johnson RL; Ryan KA; Hall Y; Carroll MW; Issa F; Balfe P; Wack A; Bishop T; Salguero FJ; McKeating JA
PLoS Pathog; 2022 Sep; 18(9):e1010807. PubMed ID: 36067210
[TBL] [Abstract][Full Text] [Related]
16. The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury.
Ruan W; Ma X; Bang IH; Liang Y; Muehlschlegel JD; Tsai KL; Mills TW; Yuan X; Eltzschig HK
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009485
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
18. CD39 in the development and progression of pulmonary arterial hypertension.
Willcox A; Lee NT; Nandurkar HH; Sashindranath M
Purinergic Signal; 2022 Dec; 18(4):409-419. PubMed ID: 35947229
[TBL] [Abstract][Full Text] [Related]
19. Alternative adenosine Receptor activation: The netrin-Adora2b link.
Yuan X; Mills T; Doursout MF; Evans SE; Vidal Melo MF; Eltzschig HK
Front Pharmacol; 2022; 13():944994. PubMed ID: 35910389
[TBL] [Abstract][Full Text] [Related]
20. 4-Pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR)-A Novel Oncometabolite Modulating Cancer-Endothelial Interactions in Breast Cancer Metastasis.
Koszalka P; Kutryb-Zajac B; Mierzejewska P; Tomczyk M; Wietrzyk J; Serafin PK; Smolenski RT; Slominska EM
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
